These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

202 related items for PubMed ID: 9748120

  • 1. Immunohistochemical detection of NAD(P)H:quinone oxidoreductase in human lung and lung tumors.
    Siegel D, Franklin WA, Ross D.
    Clin Cancer Res; 1998 Sep; 4(9):2065-70. PubMed ID: 9748120
    [Abstract] [Full Text] [Related]

  • 2. A new screening system for NAD(P)H:quinone oxidoreductase (NQO1)-directed antitumor quinones: identification of a new aziridinylbenzoquinone, RH1, as a NQO1-directed antitumor agent.
    Winski SL, Hargreaves RH, Butler J, Ross D.
    Clin Cancer Res; 1998 Dec; 4(12):3083-8. PubMed ID: 9865924
    [Abstract] [Full Text] [Related]

  • 3. Nicotinamide adenine dinucleotide (phosphate): quinone oxidoreductase (DT-diaphorase) as a target for bioreductive antitumor quinones: quinone cytotoxicity and selectivity in human lung and breast cancer cell lines.
    Beall HD, Murphy AM, Siegel D, Hargreaves RH, Butler J, Ross D.
    Mol Pharmacol; 1995 Sep; 48(3):499-504. PubMed ID: 7565631
    [Abstract] [Full Text] [Related]

  • 4. Elevated DT-diaphorase activity and messenger RNA content in human non-small cell lung carcinoma: relationship to the response of lung tumor xenografts to mitomycin Cł.
    Malkinson AM, Siegel D, Forrest GL, Gazdar AF, Oie HK, Chan DC, Bunn PA, Mabry M, Dykes DJ, Harrison SD.
    Cancer Res; 1992 Sep 01; 52(17):4752-7. PubMed ID: 1324793
    [Abstract] [Full Text] [Related]

  • 5. An alternatively spliced form of NQO1 (DT-diaphorase) messenger RNA lacking the putative quinone substrate binding site is present in human normal and tumor tissues.
    Gasdaska PY, Fisher H, Powis G.
    Cancer Res; 1995 Jun 15; 55(12):2542-7. PubMed ID: 7780966
    [Abstract] [Full Text] [Related]

  • 6. Indolequinone antitumor agents: correlation between quinone structure, rate of metabolism by recombinant human NAD(P)H:quinone oxidoreductase, and in vitro cytotoxicity.
    Beall HD, Winski S, Swann E, Hudnott AR, Cotterill AS, O'Sullivan N, Green SJ, Bien R, Siegel D, Ross D, Moody CJ.
    J Med Chem; 1998 Nov 19; 41(24):4755-66. PubMed ID: 9822546
    [Abstract] [Full Text] [Related]

  • 7. Subcellular localization of NAD(P)H:quinone oxidoreductase 1 in human cancer cells.
    Winski SL, Koutalos Y, Bentley DL, Ross D.
    Cancer Res; 2002 Mar 01; 62(5):1420-4. PubMed ID: 11888914
    [Abstract] [Full Text] [Related]

  • 8. Immunohistochemical localization of NQO1 in epithelial dysplasia and neoplasia and in donor eyes.
    Schelonka LP, Siegel D, Wilson MW, Meininger A, Ross D.
    Invest Ophthalmol Vis Sci; 2000 Jun 01; 41(7):1617-22. PubMed ID: 10845577
    [Abstract] [Full Text] [Related]

  • 9. Arsenite pretreatment enhances the cytotoxicity of mitomycin C in human cancer cell lines via increased NAD(P)H quinone oxidoreductase 1 expression.
    Lin YL, Ho IC, Su PF, Lee TC.
    Toxicol Appl Pharmacol; 2006 Aug 01; 214(3):309-17. PubMed ID: 16494910
    [Abstract] [Full Text] [Related]

  • 10. Mitogen-activated protein kinase phosphatase-1 is overexpressed in non-small cell lung cancer and is an independent predictor of outcome in patients.
    Vicent S, Garayoa M, López-Picazo JM, Lozano MD, Toledo G, Thunnissen FB, Manzano RG, Montuenga LM.
    Clin Cancer Res; 2004 Jun 01; 10(11):3639-49. PubMed ID: 15173070
    [Abstract] [Full Text] [Related]

  • 11. NAD(P)H:quinone oxidoreductase-1 overexpression predicts poor prognosis in small cell lung cancer.
    Cui X, Jin T, Wang X, Jin G, Li Z, Lin L.
    Oncol Rep; 2014 Dec 01; 32(6):2589-95. PubMed ID: 25231218
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of NQO1 gene expression and variant allele in human NSCLC tumors and matched normal lung tissue.
    Kolesar JM, Pritchard SC, Kerr KM, Kim K, Nicolson MC, McLeod H.
    Int J Oncol; 2002 Nov 01; 21(5):1119-24. PubMed ID: 12370763
    [Abstract] [Full Text] [Related]

  • 13. The effect of functional groups on reduction and activation of quinone bioreductive agents by DT-diaphorase.
    Fourie J, Oleschuk CJ, Guziec F, Guziec L, Fiterman DJ, Monterrosa C, Begleiter A.
    Cancer Chemother Pharmacol; 2002 Feb 01; 49(2):101-10. PubMed ID: 11862423
    [Abstract] [Full Text] [Related]

  • 14. Arsenite and cadmium, but not chromium, induce NAD(P)H:quinone oxidoreductase 1 through transcriptional mechanisms, in spite of post-transcriptional modifications.
    Elbekai RH, El-Kadi AO.
    Toxicol In Vitro; 2008 Aug 01; 22(5):1184-90. PubMed ID: 18474416
    [Abstract] [Full Text] [Related]

  • 15. Novel quinolinequinone antitumor agents: structure-metabolism studies with NAD(P)H:quinone oxidoreductase (NQO1).
    Fryatt T, Pettersson HI, Gardipee WT, Bray KC, Green SJ, Slawin AM, Beall HD, Moody CJ.
    Bioorg Med Chem; 2004 Apr 01; 12(7):1667-87. PubMed ID: 15028260
    [Abstract] [Full Text] [Related]

  • 16. Indolequinone antitumour agents: correlation between quinone structure and rate of metabolism by recombinant human NAD(P)H:quinone oxidoreductase.
    Newsome JJ, Swann E, Hassani M, Bray KC, Slawin AM, Beall HD, Moody CJ.
    Org Biomol Chem; 2007 May 21; 5(10):1629-40. PubMed ID: 17571194
    [Abstract] [Full Text] [Related]

  • 17. NAD(P)H:quinone oxidoreductase1 (DT-diaphorase) expression in normal and tumor tissues.
    Belinsky M, Jaiswal AK.
    Cancer Metastasis Rev; 1993 Jun 21; 12(2):103-17. PubMed ID: 8375015
    [Abstract] [Full Text] [Related]

  • 18. Natural and synthetic quinones and their reduction by the quinone reductase enzyme NQO1: from synthetic organic chemistry to compounds with anticancer potential.
    Colucci MA, Moody CJ, Couch GD.
    Org Biomol Chem; 2008 Feb 21; 6(4):637-56. PubMed ID: 18264564
    [Abstract] [Full Text] [Related]

  • 19. C609T polymorphism of NAD(P)H quinone oxidoreductase 1 as a predictive biomarker for response to amrubicin.
    Takakuwa O, Oguri T, Ozasa H, Uemura T, Kunii E, Kasai D, Miyazaki M, Maeno K, Sato S.
    J Thorac Oncol; 2011 Nov 21; 6(11):1826-32. PubMed ID: 21964527
    [Abstract] [Full Text] [Related]

  • 20. The Cap'n'Collar basic leucine zipper transcription factor Nrf2 (NF-E2 p45-related factor 2) controls both constitutive and inducible expression of intestinal detoxification and glutathione biosynthetic enzymes.
    McMahon M, Itoh K, Yamamoto M, Chanas SA, Henderson CJ, McLellan LI, Wolf CR, Cavin C, Hayes JD.
    Cancer Res; 2001 Apr 15; 61(8):3299-307. PubMed ID: 11309284
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.